JP2015531351A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531351A5
JP2015531351A5 JP2015533237A JP2015533237A JP2015531351A5 JP 2015531351 A5 JP2015531351 A5 JP 2015531351A5 JP 2015533237 A JP2015533237 A JP 2015533237A JP 2015533237 A JP2015533237 A JP 2015533237A JP 2015531351 A5 JP2015531351 A5 JP 2015531351A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
unsubstituted
fluorophenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015533237A
Other languages
English (en)
Japanese (ja)
Other versions
JP6469009B2 (ja
JP2015531351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/061050 external-priority patent/WO2014047519A2/en
Publication of JP2015531351A publication Critical patent/JP2015531351A/ja
Publication of JP2015531351A5 publication Critical patent/JP2015531351A5/ja
Application granted granted Critical
Publication of JP6469009B2 publication Critical patent/JP6469009B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015533237A 2012-09-21 2013-09-20 がん処置用β−ヒドロキシラーゼ阻害剤 Expired - Fee Related JP6469009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261704014P 2012-09-21 2012-09-21
US61/704,014 2012-09-21
PCT/US2013/061050 WO2014047519A2 (en) 2012-09-21 2013-09-20 Inhibitors of beta-hydrolase for treatment of cancer

Publications (3)

Publication Number Publication Date
JP2015531351A JP2015531351A (ja) 2015-11-02
JP2015531351A5 true JP2015531351A5 (cg-RX-API-DMAC10.html) 2016-11-10
JP6469009B2 JP6469009B2 (ja) 2019-02-13

Family

ID=50342080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533237A Expired - Fee Related JP6469009B2 (ja) 2012-09-21 2013-09-20 がん処置用β−ヒドロキシラーゼ阻害剤

Country Status (10)

Country Link
US (8) US9771356B2 (cg-RX-API-DMAC10.html)
EP (2) EP3345596B1 (cg-RX-API-DMAC10.html)
JP (1) JP6469009B2 (cg-RX-API-DMAC10.html)
KR (1) KR102137180B1 (cg-RX-API-DMAC10.html)
CN (2) CN110818660B (cg-RX-API-DMAC10.html)
AU (1) AU2013317791B2 (cg-RX-API-DMAC10.html)
CA (1) CA2885762C (cg-RX-API-DMAC10.html)
ES (2) ES2865412T3 (cg-RX-API-DMAC10.html)
HK (1) HK1208805A1 (cg-RX-API-DMAC10.html)
WO (2) WO2014047519A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345596B1 (en) 2012-09-21 2021-01-20 Rhode Island Hospital Inhibitors of beta-hydrolase for treatment of cancer
WO2019012159A1 (en) * 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
WO2019246093A1 (en) * 2018-06-18 2019-12-26 Midwestern University Monoclonal antibodies targeting epitopes of asph
CN109364251A (zh) * 2018-12-06 2019-02-22 苏州大学 Tet蛋白在治疗抑郁症中的应用
KR20210129115A (ko) * 2019-02-15 2021-10-27 미드웨스턴 유니버시티 동위원소-안정화된 테트론이미드 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE39717C (de) H. LEHMANN in München, Enhuberstr. 5 part Bleistifthalter
DD39717A (cg-RX-API-DMAC10.html) *
JPS63500375A (ja) * 1985-08-02 1988-02-12 シエブロン リサ−チ カンパニ− 除草性2−(オクサまたはチアヘテロサイクル)5−アミノ−3−オクソ−4−(置換−フェニル)−2、3−ジヒドロフラン類
US5314913A (en) * 1992-12-08 1994-05-24 American Home Products Corporation 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones
US5698585A (en) * 1995-04-13 1997-12-16 Kikkoman Corporation Pharmaceutical preparation for prevention and/or treatment for cataract
JPH09110853A (ja) * 1995-10-12 1997-04-28 Kikkoman Corp 4‐アシルオキシフラノン誘導体又はその塩及びその製造方法
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
WO1998041516A1 (en) 1997-03-14 1998-09-24 Merck Frosst Canada & Co. (methylsulfonyl)phenyl-2-(5h)-furanones with oxygen link as cox-2 inhibitors
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
US6667330B2 (en) * 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
AU2002950862A0 (en) 2002-08-19 2002-09-12 Biosignal Pty Ltd Furanone derivatives and methods of making same
EP1554394B1 (en) 2002-10-16 2009-12-16 Isis Innovation Limited Screening methods using a structural model of FIH
WO2005070916A1 (en) * 2004-01-09 2005-08-04 Eli Lilly And Company Thiophene and furan compounds
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
EP2576532B1 (en) * 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
EP3345596B1 (en) 2012-09-21 2021-01-20 Rhode Island Hospital Inhibitors of beta-hydrolase for treatment of cancer

Similar Documents

Publication Publication Date Title
EP2807164B1 (en) Imidazopyrrolidinone compounds
US8859586B2 (en) Cyclohexyl isoquinolinone compounds
AU766081B2 (en) Phthalazine derivatives for treating inflammatory diseases
EP2721008B1 (en) Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
EP2948451B1 (en) Substituted purinone compounds
JP2020505396A5 (cg-RX-API-DMAC10.html)
EP2785717A1 (en) Pyrazolopyrrolidine compounds
MX2010011097A (es) Compuesto de aciltiourea o sal del mismo, y uso del mismo.
BR112017016465B1 (pt) Composto heterocíclico e composição farmacêutica que o compreende
WO2013173254A1 (en) Bicyclic compounds as kinases inhibitors
JPWO2013100014A1 (ja) 抗腫瘍剤の効果増強剤
CN110507654A (zh) 有酪氨酸激酶抑制剂的组合产品和其应用
JP2005526794A5 (ja) ベンズイミダゾールおよびマイトジェン活性化およびrhoキナーゼ阻害剤としてのその使用
US20170209457A1 (en) Combination Therapy
CA3075870A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
WO2016159301A1 (ja) 慢性骨髄性白血病治療剤
JP2016196411A (ja) 腫瘍治療剤
AU2019341976A1 (en) Cancer combination therapy using quinoline carboxamide derivative
JPWO2015122504A1 (ja) キナーゼ阻害剤
WO2014139391A1 (en) Substituted pyridine compounds as kinases inhibitors
HK1198761B (en) Imidazopyrrolidinone compounds